【드래곤 스포츠】 보증업체놀이터추천홍보 : 프로그램제작판매제작의뢰 : 스포츠분석 : 무료스포츠중계tv : 섹시bj움짤 : 뉴스 : 안구정화

로그인

글쓰기

[IT뉴스]BioDyne Enters Revenue Phase in Roche Deal[K-Bio Pulse]

온카뱅크관리자

2025-12-19 08:17:31

<div class="article_view" data-translation-body="true" data-tiara-layer="article_body" data-tiara-action-name="본문이미지확대_클릭"> 
 <section dmcf-sid="4xOjhumjDD">
 [Kim Jiwan, Edaily Reporter] The Korean biotech market on the 11th was driven by a trio of positive catalysts across technology licensing, regulatory momentum, and clinical progress. Companies benefiting from these themes led the day’s trading.
 <figure class="figure_frm origin_fig" contents-hash="57fb62bbf006dc23c666d84c61654e257d6e8386e59adfaad66dc5202f380269" dmcf-pid="6oWsHVTsIk" dmcf-ptype="figure">
 <img alt="Roche’s Ventana SP400 Cervical Cancer Diagnostic Device Built on BioDyne’s Blowing Technology" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202512/19/Edaily/20251219081406334ciyu.jpg" data-org-width="658" dmcf-mid="9cz0fAb0ws" dmcf-mtype="image" height="auto" src="https://img3.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202512/19/Edaily/20251219081406334ciyu.jpg" width="658">
 <figcaption class="txt_caption default_figure">
 Roche’s Ventana SP400 Cervical Cancer Diagnostic Device Built on BioDyne’s Blowing Technology
 </figcaption>
 </figure>
 BioDyne advanced on expectations surrounding the commercialization of its Roche partnered diagnostic platform while the government’s new healthcare AI data policy boosted Geninus. Meanwhile Aptabio surged as its kidney disease program continued to show steady clinical progress.
 BioDyne Rises on Revenue Momentum
 BioDyne shares climbed after news that its exclusive global agreement with Roche has entered a revenue-generating phase. The stock closed at 16,310 won, up 8.73 percent. A PharmiDaily report highlighting BioDyne’s shift toward profitability also supported sentiment.
 The company received a final milestone payment of 250,000 dollars, marking the commercial start of Roche’s Ventana SP400 diagnostic device. Total milestone payments under the deal are 6.75 million dollars. SP400 is currently sold only in Japan, with rollout to more than 40 countries planned for next year. Royalties from Japan should begin in the first quarter.
 A company official said the launch marks a real inflection point for the 2019 Roche partnership. After years of losses linked to pandemic delays BioDyne’s earnings outlook is improving. Demand for cervical cancer screening is rising globally and sales of PathExplorer and related reagents are expected to grow 20 to 30 percent this year.
 The company is also preparing the launch of EarlyPop Brush a self collection cervical sampling device with no major competitors. A 520 patient Korean study is complete and CE related publication is underway.
 Senior executives recently bought shares calling the stock undervalued. Analysts expect annual revenue from SP400 royalties and consumables to surpass 40 billion won from 2028.
 <figure class="figure_frm origin_fig" contents-hash="8f3386595249482c39314d97a5b2ad705c9784d20a210187ad3fdb276226257c" dmcf-pid="HBaMAGoMDL" dmcf-ptype="figure">
 <img class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202512/19/Edaily/20251219081407737hkil.jpg" data-org-width="273" dmcf-mid="2vWltPHlOm" dmcf-mtype="image" height="auto" src="https://img2.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202512/19/Edaily/20251219081407737hkil.jpg" width="658">
 </figure>
 Geninus Up on Gov’t AI Data Support
 Geninus rose on the government’s announcement of expanded support for medical AI. The stock closed at 2,810 won, up 13.54 percent. 
 The Ministry of Health and Welfare stated that it plans to strengthen public healthcare data infrastructure and broaden access for AI startups and SMEs. 
 A Geninus spokesperson said expanded data access would support the company’s genomic and spatial transcriptomics AI services. 
 CEO Park Woong-yang noted that collaborations with major pharmaceutical companies in Japan and other regions are accelerating, with several contracts already in progress.
 <figure class="figure_frm origin_fig" contents-hash="b561bf27bbb1fee7cedea859653abe18bf6c77442bd2ef0da22d9a1f5297950a" dmcf-pid="FJSDybhDDR" dmcf-ptype="figure">
 <img class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202512/19/Edaily/20251219081408973tzii.png" data-org-width="800" dmcf-mid="VRrcSzOcsr" dmcf-mtype="image" height="auto" src="https://img2.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202512/19/Edaily/20251219081408973tzii.png" width="658">
 </figure>
 Aptabio Up on Smooth Trial Progress
 Aptabio also gained sharply as its diabetic kidney disease candidate APX-115 continued its successful clinical trajectory. The stock closed at 10,420 won, up 12.28 percent. 
 The company said approximately 30 percent of the target 186 patients in the global phase 2b trial have already been dosed. Interim results are planned for late next year with final dosing targeted by year-end.
 In a previous European phase 2a study involving 140 patients, APX-115 showed clear benefit in moderate to severe patients, reducing urine albumin creatinine ratio by about 50 percent versus placebo.
 <figure class="figure_frm origin_fig" contents-hash="881f57a71a58326006a0e16a65407e09b07f000c002d72556f37ce51cac5591c" dmcf-pid="udlETBCEO6" dmcf-ptype="figure">
 <img alt="The American Society of Nephrology (ASN) 2025, held in Houston, USA from November 5–9 (Photo: Aptabio)" class="thumb_g_article" data-org-src="https://t1.daumcdn.net/news/202512/19/Edaily/20251219081410197fqgr.jpg" data-org-width="507" dmcf-mid="ftNRcHgRDw" dmcf-mtype="image" height="auto" src="https://img4.daumcdn.net/thumb/R658x0.q70/?fname=https://t1.daumcdn.net/news/202512/19/Edaily/20251219081410197fqgr.jpg" width="658">
 <figcaption class="txt_caption default_figure">
 The American Society of Nephrology (ASN) 2025, held in Houston, USA from November 5–9 (Photo: Aptabio)
 </figcaption>
 </figure>
 The product had been featured as a key clinical highlight at the American Society of Nephrology’s Kidney Week in 2022. APX-115 works by regulating excessive reactive oxygen species in the kidney through inhibition of NADPH oxidase.
 CEO Lee Soo-jin said enrollment and dosing are progressing smoothly and added that the company aims to validate efficacy in the ongoing study while advancing global licensing and commercialization plans.
 김지완 (2pac@edaily.co.kr) 
 </section> 
 </div> 
 Copyright © 이데일리. 무단전재 및 재배포 금지.

댓글 총 0개

이번주 포인트랭킹

매주 일요일 밤 0시에 랭킹을 초기화합니다.

14,000상품권
23,000상품권
32,000상품권

업체홍보/구인 더보기

지식/노하우 더보기

판매의뢰 더보기

포토 더보기